This paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property rights.
Sharon Flank
Advertisement
Sharon Flank, PhD, sflank@infratrac.com, is CEO at InfraTrac.
Articles by Sharon Flank
Advertisement
Latest Updated Articles
Legal and Regulatory Perspectives on 3D Printing: Drug Compounding ApplicationsPublished: December 10th 2024 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
PharmTech Weekly News Roundup – Week of November 3, 2025
2
Why Investment Strategies Matter for Advancing Pharmaceutical Technologies
3
New Dosage Forms and Delivery Systems Driving 505(b)(2) Success
4
AAPS PharmSci 360: Enhancing Bioanalysis with AI and Other Technologies
5
